招商通知： 第三届全球手术机器人大会 # 研究背景 左心耳是心房颤动异位激动和左心房血栓的重要来源，隔绝左心耳有助于减少脑卒中发生和血栓形成。 Atricure 是全球最早进入该领域的公司， 2010 年首款产品 AtriClip 经 FDA 批准在美国上市，迄今在全 球植入超过 65 万例 ，是目前 全球应用最多的左心耳闭合器。 2023 年底， 美敦力 的 Penditure 经 FDA 批准在美国上市，是 全球第 2 款一端开口的左心耳闭合器械 。 领健医疗 的 V-Clip ® 是 全球第 3 款获批的一端开口的左心耳闭合器械 。 V-Clip ® 作为 我国首个、全球第 3 款 问世的 V 型单端开口闭合夹式系统 ，其突破性结构设计显著优化 了左心耳的捕获与闭合效果，有效攻克了传统封堵器械因形态匹配问题产生的残余渗漏难题。该系统兼容 心脏开胸手术及微创入路，实施左心耳夹闭后，可大幅削减源自心脏的卒中风险，并降低患者对抗凝药物 的长期需求 。 心未来 近日， 北京领健医疗科技有限公司 （简称" 领健医疗 "）自主研发的 国内首款V型左心耳闭合系统V- Clip ® 正式获得NMPA 批准上市（国械注准 ...

AtriCure (ATRC) FY Conference Summary Company Overview - **Company**: AtriCure (ATRC) - **Date of Conference**: June 09, 2025 - **Key Speaker**: Angie Weirich, Chief Financial Officer Key Points and Arguments Industry and Market Dynamics - AtriCure operates in the cardiac surgery and electrophysiology markets, focusing on atrial fibrillation (AFib) treatment and pain management solutions [3][4][19] - The company emphasizes the importance of preventative care in cardiac surgery, highlighting the LEAPS clinical trial and BOXNOAF trial as significant initiatives [3][4][22] Product Portfolio and Innovations - AtriCure's product portfolio includes PFA catheters and the AtriClip device, which are critical in the treatment of AFib and appendage management [4][20] - The company launched the AtriClip Flex Mini and Cryosphere Max probes, contributing to a 14% overall growth in the first quarter [39][28] - AtriCure is focused on expanding its appendage management franchise, with a new generation of AtriClip devices that are smaller and less invasive [20][21] Financial Performance and Growth Projections - AtriCure projects a top-line growth of 11% to 13% for the year, with a strong start at 14% [37][39] - The company is committed to improving profitability alongside double-digit revenue growth, despite facing challenges in the minimally invasive business segment [5][12][38] - The international business is growing rapidly but poses a margin headwind, with potential impacts of 10 to 40 points on margin depending on the country [49][50] Competitive Landscape - AtriCure faces competition from other less invasive treatments, particularly in the PFA catheter space, which has led to distractions for electrophysiologists (EPs) [6][13][40] - The CONVERGE clinical trial is positioned as a durable option for long-standing persistent AFib patients, despite initial challenges in adoption post-launch [10][12][14] Strategic Focus and Future Outlook - The company is prioritizing resource allocation towards its appendage management and pain management segments, while maintaining a cautious approach to the CONVERGE product line [24][28] - AtriCure is exploring new markets, including below-the-knee amputations, with the Cryo XT device set to launch later this year [29][30] - The long-term revenue target is set at $1 billion by 2030, with a focus on accelerating growth through clinical trials and market expansion [69][70] Operational Efficiency and Cost Management - AtriCure is focused on leveraging SG&A expenses and improving gross margins through new product launches and operational efficiencies [58][60] - The company has made significant investments in R&D, particularly in the LEAPS clinical trial, which is expected to yield long-term benefits [61][73] Capital Allocation and M&A Strategy - AtriCure is currently focused on organic growth opportunities rather than acquisitions, emphasizing the importance of maintaining profitability [81][82] - The company is cautious about pursuing M&A that could negatively impact its bottom line trajectory [82] Additional Important Insights - The company is seeing an increase in new accounts despite the competitive pressures from PFA technology [17][24] - AtriCure's approach to training and education for healthcare practitioners has evolved, focusing on impactful methods to enhance customer engagement [62][63] - The management remains optimistic about the future, aiming to continue expanding its addressable market and driving revenue growth [84]

Creating a World Class Platform Investor Presentation April 2025 © 2025 AtriCure, Inc. All rights reserved. Forward Looking Statements and Non-GAAP Financial Measures This presentation and oral statements made in connection with this presentation contain "forward-looking statements," which are statements related to future events that by their nature address matters that are uncertain. Forward-looking statements address, among other things, AtriCure's expected market opportunity, guidance, future business, f ...